{"id":"NCT00781859","sponsor":"ThromboGenics","briefTitle":"Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.","officialTitle":"A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-03","completion":"2010-04","firstPosted":"2008-10-29","resultsPosted":"2013-01-28","lastUpdate":"2014-12-17"},"enrollment":326,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Vitreomacular Adhesion"],"interventions":[{"type":"DRUG","name":"125 µg Ocriplasmin","otherNames":["microplasmin"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"125µg Ocriplasmin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.","primaryOutcome":{"measure":"Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28.","timeFrame":"Day 28","effectByArm":[{"arm":"Ocriplasmin 125µg","deltaMin":27.9,"sd":null},{"arm":"Placebo","deltaMin":13.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":41,"countries":["United States"]},"refs":{"pmids":["26068086","23033391","22894573","22879421"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":220},"commonTop":["Vitreous floaters","Conjunctival Hemorrhage","Photopsia","Eye pain","Vision blurred"]}}